We are live on ! Find out more
BSX icon

Boston Scientific

730 hedge funds and large institutions have $44.9B invested in Boston Scientific in 2018 Q4 according to their latest regulatory filings, with 107 funds opening new positions, 257 increasing their positions, 245 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more call options, than puts

Call options by funds: $176M | Put options by funds: $85.6M

55% more first-time investments, than exits

New positions opened: 107 | Existing positions closed: 69

11% more funds holding in top 10

Funds holding in top 10: 1820 (+2)

5% more funds holding

Funds holding: 698730 (+32)

5% more repeat investments, than reductions

Existing positions increased: 257 | Existing positions reduced: 245

0.24% less ownership

Funds ownership: 92.42%92.18% (-0.24%)

9% less capital invested

Capital invested by funds: $49.2B → $44.9B (-$4.31B)

Holders
730
Holders Change
+32
Holders Change %
+4.58%
% of All Funds
16.27%
Holding in Top 10
20
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+11.11%
% of All Funds
0.45%
New
107
Increased
257
Reduced
245
Closed
69
Calls
$176M
Puts
$85.6M
Net Calls
+$90M
Net Calls Change
-$42.1M
Name Holding Trade Value Shares
Change
Change in
Stake
AG
326
Advisor Group
Arizona
$1.91M +$818K +22,544 +71%
AF
327
Advisornet Financial
Minnesota
$1.9M +$19.6K +541 +1%
CA
328
Commerzbank Aktiengesellschaft
Germany
$1.88M +$828K +22,823 +75%
PCM
329
Prelude Capital Management
New York
$1.87M +$1.03M +28,358 +116%
LTFS
330
Ladenburg Thalmann Financial Services
Florida
$1.86M +$722K +19,908 +61%
SG
331
Somerset Group
Minnesota
$1.82M +$13.3K +367 +0.7%
Creative Planning
332
Creative Planning
Kansas
$1.79M +$54.6K +1,505 +3%
SAM
333
Strategy Asset Managers
California
$1.73M -$1.57M -43,191 -47%
Wealthfront Advisers
334
Wealthfront Advisers
California
$1.68M +$1.72M +47,552 New
PA
335
Profund Advisors
Maryland
$1.68M -$414K -11,424 -19%
JG
336
Jefferies Group
New York
$1.67M +$505K +13,936 +42%
HPCM
337
High Pointe Capital Management
Illinois
$1.61M -$9.07K -250 -0.5%
EP
338
Elkfork Partners
Oregon
$1.6M +$483K +13,310 +42%
Truist Financial
339
Truist Financial
North Carolina
$1.58M +$586K +16,146 +57%
PTC
340
Private Trust Company
Ohio
$1.55M -$224K -6,163 -12%
QSS
341
Quantitative Systematic Strategies
Florida
$1.54M +$17.1K +472 +1%
MME
342
Meag Munich Ergo
Germany
$1.54M -$1.43M -39,296 -47%
B
343
Barings
North Carolina
$1.53M -$75.5K -2,082 -5%
GGHC
344
Gilder Gagnon Howe & Co
New York
$1.5M -$3.37K -93 -0.2%
SL
345
Signition LP
New York
$1.49M -$2.26M -62,426 -60%
MC
346
Moors & Cabot
Massachusetts
$1.48M +$46.2K +1,275 +3%
AP
347
Advisor Partners
California
$1.46M +$230K +6,343 +18%
FIM
348
Fernwood Investment Management
Massachusetts
$1.45M -$21.8K -600 -1%
KOCAA
349
Knights of Columbus Asset Advisors
Connecticut
$1.42M -$10.9K -300 -0.7%
NSEDCP
350
NJ State Employees Deferred Compensation Plan
New Jersey
$1.41M

BSX Hedge Fund Activity: Q4 2018 in Review

730 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q4 2018, worth a combined $44.9B — down 8.8% from $49.2B a quarter earlier.

Buyers outnumbered sellers: 107 funds opened new BSX positions and 69 closed out — a net gain of 38 holders — while 257 added to existing stakes and 245 trimmed.

The largest buyer was Capital World Investors, adding an estimated $366M. The largest seller was Fidelity Investments, cutting an estimated $462M.

  • 730 institutional investors held Boston Scientific (BSX) as of Q4 2018, up from 698 in Q3 2018.
  • Funds reported $44.9B of Boston Scientific stock for Q4 2018, down 8.8% quarter-over-quarter.
  • 107 funds opened new Boston Scientific positions in Q4 2018 and 69 closed out, a net change of +38 holders.
  • The largest Boston Scientific buyer in Q4 2018 was Capital World Investors, an estimated $366M added.
  • The largest Boston Scientific seller in Q4 2018 was Fidelity Investments, an estimated $462M sold.

Based on aggregated 13F filings for Q4 2018.